Abstract LB-302: A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumorsJean‐Charles Soria, Luca Gianni, Nathalie Lassau et al.|Cancer Research|2008Cited by 8